BeOne Medicines price to free cash flow ONC

Market value divided by free cash flow over the last twelve months, since 2025.

Today, Oct 23, 2026: 32.3×
Peer median: 22.5×

BeOne Medicines' price to free cash flow is 32.3× as of Oct 23, 2026.

The median for 10 biotech stocks of a similar size is 22.5×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	32.3×	26.4×	73.6×
2025	63.5×	63.5×	155×

Against its peers

Companies in Biotechnology nearest BeOne Medicines' size, closest first, today.

Company	Price to free cash flow
ONCBeOne Medicines	32.3×
ALNYAlnylam Pharmaceuticals	37.8×
UTHRUnited Therapeutics	23.1×
INCYIncyte	12.2×
REGNRegeneron Pharmaceuticals	22.0×
EXELExelixis	13.6×
NBIXNeurocrine Biosciences	16.7×
HALOHalozyme Therapeutics	17.7×
VRTXVertex Pharmaceuticals	35.0×
TECHBIO-TECHNE	43.2×
RGENRepligen	89.2×
Peer median	22.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on BeOne Medicines

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.